141 related articles for article (PubMed ID: 38297524)
1. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial.
Tascilar K; Hagen M; Kleyer A; Simon D; Reiser M; Hueber AJ; Manger B; Englbrecht M; Finzel S; Tony HP; Schuch F; Kleinert S; Wendler J; Ronneberger M; Figueiredo CP; Cobra JF; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Lorenz HM; Nuesslein H; Alten R; Kruger K; Henes J; Schett G; Rech J
Lancet Rheumatol; 2021 Nov; 3(11):e767-e777. PubMed ID: 38297524
[TBL] [Abstract][Full Text] [Related]
2. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.
Kjørholt KE; Sundlisæter NP; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Kvien TK; Solomon DH; van der Heijde D; Haavardsholm EA; Lillegraven S
Lancet Rheumatol; 2024 May; 6(5):e268-e278. PubMed ID: 38583450
[TBL] [Abstract][Full Text] [Related]
3. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
[TBL] [Abstract][Full Text] [Related]
4. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Burmester GR; Buttgereit F; Bernasconi C; Álvaro-Gracia JM; Castro N; Dougados M; Gabay C; van Laar JM; Nebesky JM; Pethoe-Schramm A; Salvarani C; Donath MY; John MR;
Lancet; 2020 Jul; 396(10246):267-276. PubMed ID: 32711802
[TBL] [Abstract][Full Text] [Related]
5. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
[TBL] [Abstract][Full Text] [Related]
6. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission.
El Miedany Y; El Gaafary M; Youssef S; Ahmed I; Bahlas S; Hegazi M; Nasr A
Clin Rheumatol; 2016 Dec; 35(12):2915-2923. PubMed ID: 27658417
[TBL] [Abstract][Full Text] [Related]
7. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
[TBL] [Abstract][Full Text] [Related]
9. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.
de Moel EC; Rech J; Mahler M; Roth J; Vogl T; Schouffoer A; Goekoop RJ; Huizinga TWJ; Allaart CF; Toes REM; Schett G; van der Woude D
Arthritis Res Ther; 2019 Dec; 21(1):268. PubMed ID: 31805992
[TBL] [Abstract][Full Text] [Related]
10. Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO Trial.
Stephan M; Tascilar K; Yalcin-Mutlu M; Hagen M; Haschka J; Reiser M; Hartmann F; Kleyer A; Hueber AJ; Manger B; Figueiredo C; Cobra JF; Tony HP; Finzel S; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Lorenz HM; Nüsslein H; Alten R; Henes J; Krüger K; Schett G; Rech J
J Clin Med; 2023 May; 12(11):. PubMed ID: 37297917
[TBL] [Abstract][Full Text] [Related]
11. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study.
Emery P; Burmester GR; Naredo E; Sinigaglia L; Lagunes I; Koenigsbauer F; Conaghan PG
Ann Rheum Dis; 2020 Aug; 79(8):1023-1030. PubMed ID: 32404343
[TBL] [Abstract][Full Text] [Related]
13. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.
Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Lexberg ÅS; Madland TM; Fremstad H; Høili CA; Bakland G; Spada C; Haukeland H; Hansen IM; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
Ann Rheum Dis; 2023 Nov; 82(11):1394-1403. PubMed ID: 37607809
[TBL] [Abstract][Full Text] [Related]
14. Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.
Ghiti Moghadam M; Vonkeman HE; Ten Klooster PM; Tekstra J; van Schaardenburg D; Starmans-Kool M; Brouwer E; Bos R; Lems WF; Colin EM; Allaart CF; Meek IL; Landewé R; Bernelot Moens HJ; van Riel PL; van de Laar MA; Jansen TL;
Arthritis Rheumatol; 2016 Aug; 68(8):1810-7. PubMed ID: 26866428
[TBL] [Abstract][Full Text] [Related]
15. Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
JAMA; 2021 May; 325(17):1755-1764. PubMed ID: 33944875
[TBL] [Abstract][Full Text] [Related]
16. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.
Porter D; van Melckebeke J; Dale J; Messow CM; McConnachie A; Walker A; Munro R; McLaren J; McRorie E; Packham J; Buckley CD; Harvie J; Taylor P; Choy E; Pitzalis C; McInnes IB
Lancet; 2016 Jul; 388(10041):239-47. PubMed ID: 27197690
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial.
Colmegna I; Useche ML; Rodriguez K; McCormack D; Alfonso G; Patel A; Ramanakumar AV; Rahme E; Bernatsky S; Hudson M; Ward BJ
Lancet Rheumatol; 2020 Jan; 2(1):e14-e23. PubMed ID: 38258270
[TBL] [Abstract][Full Text] [Related]
18. Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.
Hagen M; Englbrecht M; Haschka J; Reiser M; Kleyer A; Hueber A; Manger B; Figueiredo C; Cobra JF; Tony HP; Finzel S; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Lorenz HM; Nüsslein H; Alten R; Henes J; Krüger K; Schett G; Rech J
J Rheumatol; 2019 May; 46(5):460-466. PubMed ID: 30504510
[TBL] [Abstract][Full Text] [Related]
19. Predicting Flare in Patients With Rheumatoid Arthritis in Biologic Induced Remission, on Tapering, and on Stable Therapy.
Gul H; Di Matteo A; Anioke I; Shuweidhi F; Mankia K; Ponchel F; Emery P
ACR Open Rheumatol; 2024 May; 6(5):294-303. PubMed ID: 38411023
[TBL] [Abstract][Full Text] [Related]
20. A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort.
Tageldin M; Wilson N; Yin Y; Sharma TS
Rheumatology (Oxford); 2023 Oct; 62(Suppl_4):iv8-iv13. PubMed ID: 37855679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
